Onfi™ (clobazam) tablets now available in the US at retail pharmacies
3 January 2012 | By H. Lundbeck A/S
Lundbeck announced that Onfi tablets are now available for prescribing in the United States...
List view / Grid view
3 January 2012 | By H. Lundbeck A/S
Lundbeck announced that Onfi tablets are now available for prescribing in the United States...
1 January 2012 | By Teva
Dr. Jeremy Levin, a former Senior Executive at Bristol-Myers Squibb, to succeed Shlomo Yanai as President and CEO...
30 December 2011 | By Pfizer
First pneumococcal conjugate vaccine for adults 50+ has potential to help address high incidence of pneumococcal pneumonia...
29 December 2011 | By Amgen
FDA has invited Amgen to participate in a meeting of the ODAC on Feb. 8, 2012 to discuss the sBLA for XGEVA® (denosumab)...
29 December 2011 | By Janssen Research & Development, LLC
Janssen Research & Development, LLC (JRD) have announced that it has submitted a sNDA to the FDA seeking approval for the use of XARELTO® (rivaroxaban)...
27 December 2011 | By ICON plc
ICON plc., has announced the retirement of Non-Executive Director, Dr. Anthony Murphy to become effective on 31st December 2011...
20 December 2011 | By Bayer HealthCare
The only new oral anticoagulant approved in three indications across all 27 EU member states...
20 December 2011 | By Alkermes
ALKS 9070 is designed to offer once-monthly version of Aripiprazole...
20 December 2011 | By AstraZeneca
With associated impairment charges, company confirms full year financial target...
19 December 2011 | By Roche
For the treatment of people with BRAF mutation-positive metastatic melanoma...
19 December 2011 | By Pfizer
Patients with Restless Legs Syndrome (RLS) show significant benefit...
19 December 2011 | By GlaxoSmithKline
Move aims to protect millions more children in the world's poorest countries from pneumococcal disease...
19 December 2011 | By Amgen
Kevin W. Sharer has announced his plan to retire from the Company at the end of 2012...
15 December 2011 | By
The companies have expanded the strategic partnership formed last year...
15 December 2011 | By Bayer HealthCare
Once approved, the new low dose IUS will offer contraception for up to three years...